Global Healthcare Analyst

Tina Banerjee

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare companies. I have been helping investors to find future winners in healthcare space to grow their wealth by focusing on the strength and potential of the business models of the companies. My initiating coverage reports and pitch help investors to know ‘what to buy’, ‘why to buy’, and ‘when to buy’. My clients always remain on top of the sector with the help of my timely and detailed notes on earnings or any news update. I also provide broader view on the entire healthcare sector through periodic thematic reports.

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/wuxi-biologics-cayman-inc" target="_blank" data-smartkarma-citation="entities:23679:1" rel="noopener">Wuxi Biologics (2269 HK)</a> announced 1H26 result, with double-digit revenue growth and improved profitability. Resilient U.S. business, China business rebound, and significant improvement in gross margin are the key highlights.</li>
<li>The company added 169 new integrated projects in 1H26, including a record-high 123 organically added projects (+43% YoY). Total backlog reached $25.1B (up 25% YoY) as of June 30, 2026.</li>
<li>Wuxi Biologics has raised 2026 revenue growth guidance to 20–23% YoY in constant currency (vs prior 16–20% YoY) and 15–18% YoY reported (vs prior 13–17% YoY).</li>
</ul>



Wuxi Biologics (2269 HK) announced 1H26 result, with double-digit revenue growth and improved profitability. Resilient U.S. business, China business rebound, and significant improvement in gross margin are the key highlights.
The company added 169 new integrated projects in 1H26, including a record-high 123 organically added projects (+43% YoY). Total backlog reached $25.1B (up 25% YoY) as of June 30, 2026.
Wuxi Biologics has raised 2026 revenue growth guidance to 20–23% YoY in constant currency (vs prior 16–20% YoY) and 15–18% YoY reported (vs prior 13–17% YoY).


Wuxi Biologics (2269 HK): Integrated Projects Drive Accelerated 1H Growth; FY Guidance Raised